Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Iovance Biotherapeutics

Main focus: Tumor infiltrating lymphocyte (TIL) therapies for the treatment of cancer

Company stage: Clinical

Diseases (gene editing): Cancer

Genome editing tool: TALEN

Funding stage: Public (NASDAQ:IOVA)

Location: San Carlos, CA, USA



Gene-editing partnerships: Cellectis

Iovance Biotherapeutics is a clinical stage company focusing on the development of cellular therapies. The company develops tumour infiltrating lymphocyte (TIL)-based therapies to treat various types of solid tumours. The company's engagemen in the gene-editing space comes through its collaboration with Cellectis, from which it has licenced the TALEN technology to develop PD-1 inactivated TILs.


HashtagIovance Biotherapeutics

Company: Iovance Biotherapeutics
Search CRISPR Medicine